Materias dentro de su búsqueda.
Mostrando 5,481 - 5,500 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.35s Limitar resultados
  1. 5481
    “…Six hours after her mother’s death, she was admitted to our emergency department due to sudden onset of left low back pain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Sudden onset of artery dissection in a 32-year-old woman with vascular Ehlers-Danlos syndrome due to psychological stress of her mother’s death: a case series
  2. 5482
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
  3. 5483
    “…However we failed to detect any correlation between p185(HER‐2/neu) and p21(CIP1/WAF1) expression. Our results suggested that expression of both p185(HER‐2/neu) and p21(CIP1/WAF1) is concordant between primary and metastatic tumors.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    p185(HER‐2/neu) and p21(CIP1/WAF1) Expression in Primary Tumors and Lymph Node Metastases in Non‐small Cell Lung Cancer
  4. 5484
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
  5. 5485
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Muc4\sialomucin Complex, A Specific Intramembrane Modulator of ERBB2/HER2/NEU, Potentiates Primary Tumor Growth and Suppresses Apoptosis in A Xenotransplanted Melanoma
  6. 5486
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
  7. 5487
    “…Human epidermal growth factor receptor 2 (HER2) is a key tumor marker for several common and deadly cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Abnormal Anionic Porphyrin Sensing Effect for HER2 Gene Related DNA Detection via Impedance Difference between MWCNTs and Single-Stranded DNA or Double-Stranded DNA
  8. 5488
    por Zhang, Ping, Nie, Xin, Wang, Bing, Li, Lin
    Publicado 2018
    “…Several mechanisms have been identified, including EGFR T790M mutation and HER2 amplification. Herein, we present the case of a patient who progressed on first‐generation EGFR‐TKIs and developed EGFR T790M mutation, HER2 amplification, and HER2 mutation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
  9. 5489
    “…We evaluated gene amplification, copy number variations (CNVs), mRNA and protein expression of all four HER family members. In addition, our analysis included the evaluation of several other factors by immunohistochemistry (IHC), such as pHER2(Tyr1221/1222), pHER2(Tyr877) and PTEN. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
  10. 5490
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
  11. 5491
    “…Lead derivatives of 2-cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides 1–18 were synthesized, characterized and evaluated in vitro against HER-2 overexpressed breast cancer cell line SKBr-3. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lead Optimization of 2-Cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides for Targeting the HER-2 Overexpressed Breast Cancer Cell Line SKBr-3
  12. 5492
    Publicado 2019
    “…Several studies have shown that the efficacy of pemetrexed in HER2-mutant NSCLC is controversial. The aim of this study is to investigate the efficacy of pemetrexed combined with platinum chemotherapy in patients with HER2-mutant and HER2 wild-type lung adenocarcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2基因状态与晚期肺腺癌患者一线培美曲塞联合铂类化疗疗效的关系
  13. 5493
    “…OBJECTIVES: We report a clinical, outcome and epidemiological characteristics of a 36‐week pregnant woman infected with A/H5N1 and her newborn in Soc Trang province of Vietnam in 2012. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Fatal avian influenza A(H5N1) infection in a 36‐week pregnant woman survived by her newborn in Sóc Trăng Province, Vietnam, 2012
  14. 5494
    “…Twenty breast cancer PDX models were generated from different molecular subtypes (overall success rate, 17.5%; 3.6% for HR(+)/HER2(−), 21.4% for HR(+)/HER2(+), 21.9% for HR(−)/HER2(+) and 22.5% for triple-negative breast cancer (TNBC)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer
  15. 5495
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1
  16. 5496
    “…Ex vivo biodistribution confirmed the data obtained by in vivo PET imaging, and site-specific (89)Zr-DFO-trastuzumab successfully detected HER2-positive tumors in PDX mouse models. Conclusion: (89)Zr-DFO-trastuzumab is well-matched for specific immuno-PET imaging of HER2-positive tumors and site-specific labeling of trastuzumab by the SiteClick(TM) technology minimizes the impact of the DFO chelator on immuno-reactivity, stability and biodistribution. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Site-specifically labeled (89)Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model
  17. 5497
    “…Introduction: Trastuzumab has become the standard treatment for both HER2-positive early and metastatic breast cancer (HER2+ eBC or mBC) since its approval. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval
  18. 5498
    “…Estrogen receptor (ER)(+)/progesterone receptor (PR)(+), human epidermal-growth factor receptor 2 (HER2)(−) BRCA and triple-negative breast cancer (TNBC) are two important subtypes of this disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of long non-coding RNA-mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER(+)/PR(+), HER2(−) and triple negative breast cancer
  19. 5499
    “…Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
  20. 5500
    por Presti, Daniele, Quaquarini, Erica
    Publicado 2019
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Herramientas de búsqueda: RSS